Literature DB >> 11916541

The diverse molecular mechanisms responsible for the actions of opioids on the cardiovascular system.

Michael K Pugsley1.   

Abstract

The actions of opioid agonist and antagonist drugs have not been well characterized in the heart and cardiovascular system. This stems from the limited role opioid receptors have been perceived to have in the regulation of the cardiovascular system. Instead, the focus of opioid receptor research, for many years, relates to the characterization of the actions of opioid drugs in analgesia associated with receptor activation in the CNS. However, recent studies suggest that opioid receptors have a role in the heart and cardiovascular system. While some of these actions may be mediated by activation of peripheral opioid receptors, others are not, and may result from direct or receptor-independent actions on cardiac tissue and the peripheral vascular system. This review will outline some of the diverse molecular mechanisms that may be responsible for the cardiovascular actions of opioids, and will characterize the role opioid receptors have in several cardiovascular pathophysiological disease states, including hypertension, heart failure, and ischaemic arrhythmogenesis. In many instances, it would appear that the effects of opioid agonists (and antagonists) in cardiovascular disease models may be mediated by opioid receptor-independent actions of these drugs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11916541     DOI: 10.1016/s0163-7258(02)00165-1

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  25 in total

Review 1.  General anesthesia in cardiac surgery: a review of drugs and practices.

Authors:  Cory M Alwardt; Daniel Redford; Douglas F Larson
Journal:  J Extra Corpor Technol       Date:  2005-06

Review 2.  Reperfusion injury: does it exist?

Authors:  Garrett J Gross; John A Auchampach
Journal:  J Mol Cell Cardiol       Date:  2006-10-27       Impact factor: 5.000

3.  Spinal Neuronal NOS Signaling Contributes to Morphine Cardioprotection in Ischemia Reperfusion Injury in Rats.

Authors:  Lingling Jiang; Jun Hu; Shufang He; Li Zhang; Ye Zhang
Journal:  J Pharmacol Exp Ther       Date:  2016-06-29       Impact factor: 4.030

4.  Older US emergency department patients are less likely to receive pain medication than younger patients: results from a national survey.

Authors:  Timothy F Platts-Mills; Denise A Esserman; D Levin Brown; Andrey V Bortsov; Philip D Sloane; Samuel A McLean
Journal:  Ann Emerg Med       Date:  2011-10-26       Impact factor: 5.721

5.  A critical appraisal of the morphine in the acute pulmonary edema: real or real uncertain?

Authors:  Alberto Dominguez-Rodriguez; Pedro Abreu-Gonzalez
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

6.  Delta-opioid augments cardiac contraction through β-adrenergic and CGRP-receptor co-signaling.

Authors:  Vince T Nguyen; Yewen Wu; Ashley N Guillory; Bradley K McConnell; Kenichi Fujise; Ming-He Huang
Journal:  Peptides       Date:  2011-11-15       Impact factor: 3.750

Review 7.  A story of two ACEs.

Authors:  Ursula Danilczyk; Urs Eriksson; Michael A Crackower; Josef M Penninger
Journal:  J Mol Med (Berl)       Date:  2003-03-28       Impact factor: 4.599

8.  Generation of a KOR-Cre knockin mouse strain to study cells involved in kappa opioid signaling.

Authors:  Xiaoyun Cai; Huizhen Huang; Marissa S Kuzirian; Lindsey M Snyder; Megumi Matsushita; Michael C Lee; Carolyn Ferguson; Gregg E Homanics; Alison L Barth; Sarah E Ross
Journal:  Genesis       Date:  2015-12-18       Impact factor: 2.487

9.  Hypertensive state, independent of hypertrophy, exhibits an attenuated decrease in systolic function on cardiac kappa-opioid receptor stimulation.

Authors:  Craig Bolte; Gilbert Newman; Jo El J Schultz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-01-30       Impact factor: 4.733

10.  Morphine is an arteriolar vasodilator in man.

Authors:  Reza Afshari; Simon R J Maxwell; David J Webb; D Nicholas Bateman
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.